Eyenovia, Inc. announced on December 6, 2024, the pricing of a registered direct offering to raise approximately $1.9 million in gross proceeds. The company entered into a securities purchase agreement with a healthcare-focused institutional investor.
The offering includes the purchase and sale of 20,085,025 shares of common stock, or common stock equivalents, and warrants to purchase up to 40,170,050 shares. The combined offering price is $0.0969 per share and accompanying warrants, with warrants exercisable at the same price.
Net proceeds from this offering are intended for working capital and general corporate purposes, including partial repayment of outstanding debt to Avenue Capital Management II, L.P. Funds will also support the advancement of the Gen-2 Optejet device, commercialization activities for Mydcombi and clobetasol propionate, and the exploration of strategic alternatives.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.